₺
16.45
Oct 4
Business Description
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS
ISIN : TRERTAL00018
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.11 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.65 | |||||
Altman Z-Score | 3.55 | |||||
Beneish M-Score | -1.3 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.1 | |||||
3-Year FCF Growth Rate | -55.8 | |||||
3-Year Book Growth Rate | 92.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.2 | |||||
9-Day RSI | 47.29 | |||||
14-Day RSI | 46.36 | |||||
6-1 Month Momentum % | 114.11 | |||||
12-1 Month Momentum % | 19.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 142.19 | |||||
Days Sales Outstanding | 113.52 | |||||
Days Payable | 93.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | 1.67 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 15.09 | |||||
Operating Margin % | -41.71 | |||||
Net Margin % | -73.45 | |||||
FCF Margin % | -96.39 | |||||
ROE % | -8.41 | |||||
ROA % | -7.04 | |||||
ROIC % | -1.74 | |||||
3-Year ROIIC % | -10.25 | |||||
ROC (Joel Greenblatt) % | -100.6 | |||||
ROCE % | -16.64 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 6.03 | |||||
PS Ratio | 12.67 | |||||
PB Ratio | 1.09 | |||||
Price-to-Tangible-Book | 1.09 | |||||
EV-to-EBIT | -8.43 | |||||
EV-to-EBITDA | -9.55 | |||||
EV-to-Revenue | 13.49 | |||||
EV-to-FCF | -13.99 | |||||
Price-to-Projected-FCF | 1.06 | |||||
Price-to-Median-PS-Value | 5.58 | |||||
Earnings Yield (Greenblatt) % | -11.86 | |||||
FCF Yield % | -7.6 | |||||
Forward Rate of Return (Yacktman) % | 20.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₺) | 129.779 | ||
EPS (TTM) (₺) | -0.953 | ||
Beta | 0 | ||
Volatility % | 150.91 | ||
14-Day RSI | 46.36 | ||
14-Day ATR (₺) | 1.560375 | ||
20-Day SMA (₺) | 17.6735 | ||
12-1 Month Momentum % | 19.9 | ||
52-Week Range (₺) | 10.45 - 32.56 | ||
Shares Outstanding (Mil) | 100 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS Stock Events
Event | Date | Price(₺) | ||
---|---|---|---|---|
No Event Data |
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS Frequently Asked Questions
What is RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS(IST:RTALB)'s stock price today?
When is next earnings date of RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS(IST:RTALB)?
Does RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret AS(IST:RTALB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |